AGM Statement

Advanced Medical Solutions Grp PLC
06 June 2007


For immediate release                                               6 June 2007



                      Advanced Medical Solutions Group plc

                            ('AMS' or 'the Company')

                             Annual General Meeting



Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global
medical technology company, today held its Annual General Meeting at which all
of the resolutions put to shareholders were duly passed.


These resolutions included a special resolution which approved the reduction of
the Company's share capital by the cancellation of its deferred shares and the
cancellation of the Company's share premium account.  Further to the
announcement of 27 April 2007, the Company will now seek the confirmation of the
proposed reduction and cancellation by the High Court of Justice.  It is
currently anticipated that the court will hear the Company's application on 4
July 2007 and that the proposed reduction and cancellation, if confirmed by the
court at that hearing, will become effective shortly thereafter upon the
registration by the Registrar of Companies of the court order and of the minute
approved by the court setting out the particulars of the Company's share capital
as altered by that order.


Don Evans, AMS' Chief Executive, gave a presentation at today's AGM, a copy of
which will be available on the Company's website, www.admedsol.com, later today.



                                   -- ENDS --



For further information, please contact:


Advanced Medical Solutions Group plc                  [phone]
Don Evans (Chief Executive Officer)
Mary Tavener (Group Finance Director)
www.admedsol.com

Buchanan Communications                               [phone]
Mark Court/Mary-Jane Johnson



Notes to Editors:



Advanced Medical Solutions is a UK based company developing and providing
leading edge technology to the $15 billion global woundcare market.

Founded in 1991 and quoted on AIM, the Company is focused on the design,
development, manufacture and sale of advanced woundcare dressings and products
for closing wounds and sealing tissue.

AMS provides a full range of advanced woundcare products for sale in hospital,
nursing home and community care markets.  The main indications are for chronic
wounds such as ulcers and pressure sores.  These products pioneer the concept of
moist wound healing to allow wounds to heal faster and with less pain and
scarring if they remain moist.  They protect the wound, deal with tissue fluids
and provide an optimal environment for healing to occur.   AMS' resources ensure
a unique position as a vertically integrated 'one stop shop' to provide all
categories of moist wound healing products. The Company has the capability to
move a product from design and development through to production and delivery
ready for distribution into customer markets.

The acquisition of MedLogic in 2002 has brought AMS products based upon
cyanoacrylate adhesive technology which allow the closure of wounds following
trauma or surgical incisions, or seal skin to protect against breakdown or wound
infection.  These products address the emerging tissue adhesives and sealants
segment of the wound closure market.



AMS' technology and products currently serve the majority of the key global
markets and strategic partners.






                      This information is provided by RNS
            The company news service from the London Stock Exchange